Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05478083
Other study ID # 2020-005949-16
Secondary ID 2020-005949-1610
Status Recruiting
Phase Phase 2
First received
Last updated
Start date June 1, 2022
Est. completion date October 1, 2027

Study information

Verified date November 2022
Source University Medical Center Groningen
Contact Ron T Gansevoort
Phone +31 50 3610923
Email r.t.gansevoort@umcg.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Multicenter trial on the effect of the GnRH analogue leuprorelin on the growth of total liver volume in pre-menopausal women with very severe polycystic liver disease who, despite available therapy, experience growth and are heading for liver transplantation.


Recruitment information / eligibility

Status Recruiting
Enrollment 36
Est. completion date October 1, 2027
Est. primary completion date June 1, 2027
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Female patients - Diagnosis of polycystic liver disease defined as the presence of more than 10 liver cysts - Age between 18 to 45 (inclusive) years; - Very large liver for age, defined as the upper 10% of liver volumes in specific age categories (based on a retrospective polycystic liver disease registry, n=1.600 patients) - 18-30 yr; height adjusted TLV > 2.0 L/m - 30-35 yr; height adjusted TLV > 2.2 L/m - 35-40 yr; height adjusted TLV > 2.5 L/m - 40-45 years; height adjusted TLV > 3.0 L/m - Availability of at least 1 historical MRI or CT scan made between 5 to 1 years before baseline visit of this study - Ongoing liver growth, defined as an increase in absolute total liver volume between the historical MRI or CT scan and the MRI at screening of this trial - Since somatostatin analogues are proven efficacious therapy for polycystic liver disease at this time it is required that: - patients use a somatostatin analogue and still have confirmed liver growth; OR - patient have a specific reason not to use this medication, .e.g. patient used a somatostatin analogue in the past, but had to stop it due to inefficacy or because he/she did not tolerate it, patient has a contra-indication for using somatostatin analogues, no availability of somatostatin analogues - Voluntary written informed consent before performance of any study-related procedures not part of standard medical care, and able to read, comprehend, and respond to study questionnaires. Exclusion Criteria: Post-menopausal status or (vasomotor) symptoms indicating upcoming menopause - Anti Mullerian Hormone (AMH) measurement at screening visit <0.03 ng/ml. - Active desire to have children, pregnancy or breast-feeding - Contra-indications for leuprorelin, such as history of cardiovascular disease, history of osteoporosis or osteoporosis determined by DEXA-scan at screening (T score = - 2.5), or a known intolerance for leuprorelin - Liver transplantation or liver surgery expected within 1.5 years, to the discretion of the study doctor - Use of hormonal oral contra-conception containing estrogen and/or progesterone. In contrast, a hormone containing uterine device is not an exclusion criteria. - Contra-indications for MRI assessments (such as implants) or not able or willing to undergo MRI scan for other reasons (e.g. claustrophobia, profound obesity) - Kidney transplantation or chronic use of immunosuppressive agents (such as cyclosporine, mycophenolic acid, tacrolimus but not prednisolone) for other indications - Severe hypertension, defined as a systolic blood pressure >160 mmHg and/or diastolic blood pressure > 100 mm Hg. - Clinically significant, uncontrolled medical condition that, in the opinion of the investigator, would put the safety of the patient at risk through participation, or which would affect the efficacy of safety analysis if the condition exacerbated during the study, or that may significantly interfere with study compliance, such as, but not restricted to, recurrent cholangitis, recurrent ascites or hepato-venous outflow obstruction, (history of) depression - Participation in other interventional studies at the same time.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Leuprorelin
Treatment consist of leuprorelin 3.75 mg once monthly for the first 3 months followed by 3-monthly injections of 11.25 mg. The direct start group will use leuprorelin for 36 months. The delayed start group will use standard of care in the first 18 months.

Locations

Country Name City State
Netherlands Groningen universitair medical center Groningen
Netherlands Radboudumc Nijmegen Gelderland

Sponsors (2)

Lead Sponsor Collaborator
University Medical Center Groningen Radboud University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Liver growth Liver volumes (in % per year) measured in the MRI at screening, 6 months, 18 months, 24 months and 36 months 36 months
Secondary Polycystic liver disease related complaints PLD related complaints assessed by the Polycystic liver disease-Questionnaire at baseline, 6 months, 18 months, 24 months and 36 months 36 months
Secondary Menopause related complaints Menopause related complaints by using the validated MENQOL questionnaire at baseline, 6 months, 18 months, 24 months and 36 months 36 months
Secondary Patient reported mental health Quality of life and as subset mental health will be measured by the validated RAND SF-36 questionnaires at baseline, 6 months, 18 months, 24 months and 36 months 36 months
Secondary Patient reported physical health Quality of life and as subset physical health will be measured by the validated RAND SF-36 questionnaires at baseline, 6 months, 18 months, 24 months and 36 months 36 months
Secondary Kidney growth Kidney volumes (in % per year) measured in the MRI at screening, 6 months, 18 months, 24 months and 36 months 36 months
Secondary Sex hormone levels Anti Muller Hormone will be assessed at screening. Other Extensive laboratory includes estradiol, progesterone, AMH, FSH, LH levels at baseline, 6 months after start therapy and after 18 and 36 months. 36 months
Secondary Bone density Bone density measured by a DEXA scan at screening, 18 months and 36 months. 36 months
Secondary Renal function eGFR measurements and 24h urine analyisis (in ADPKD patients only) at baseline, 6 months, 18 months, 24 months and 36 months time 36 months
Secondary Bloodpressure Manual blood pressure measurements in millimetres of mercury (measure 3 times with 2 minutes in between) at screening, baseline, 3 months, 6 months, 12 months, 18months, 21 months, 24 months, 30 months and 36 months . 36 months
Secondary Heart rate Heart rate in beats per minute (measure 3 times with 2 minutes in between) measured at screening, baseline, 3 months, 6 months, 12 months, 18months, 21 months, 24 months, 30 months and 36 months . 36 months
Secondary Weight Body weight in kilograms measured at screening, baseline, 3 months, 6 months, 12 months, 18months, 21 months, 24 months, 30 months and 36 months . 36 months
Secondary Upper-arm-circumference Upper-arm-circumference in centimeters of the non-dominant arm measured at screening, baseline, 3 months, 6 months, 12 months, 18months, 21 months, 24 months, 30 months and 36 months. 36 months
Secondary Abdominal circumference Abdominal circumference in centimeters (measured at the level of the umbilicus) measured at screening, baseline, 3 months, 6 months, 12 months, 18months, 21 months, 24 months, 30 months and 36 months .
At screening, length will be collected to calculate Body Mass Index.
36 months
Secondary Length At screening length in centimeters will be collected. 1 month
Secondary The number of participants experciencing a (serious) adverse events During each physical or telephone contact, the adverse effects are queried and registered in accordance with national protocol 36 months
Secondary Symptoms of depression Symptoms of depression measured by the validated BD-II questionnaires at baseline, 6 months, 18 months, 24 months and 36 months 36 months
See also
  Status Clinical Trial Phase
Recruiting NCT04310319 - Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt N/A
Recruiting NCT03596957 - Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease Phase 4
Terminated NCT04064346 - Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease Phase 3
Completed NCT03203642 - Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD Phase 2
Recruiting NCT05500157 - Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts N/A
Recruiting NCT04111692 - A Prospective Observational Study of Foam Sclerotherapy .
Recruiting NCT04907799 - Daily Caloric Restriction in ADPKD N/A
Completed NCT05401409 - Effect of Beetroot Juice on Reducing Hypertension in Autosomal Dominant Polycystic Kidney Disease N/A
Terminated NCT03918447 - A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON Phase 3
Terminated NCT03749447 - An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) Phase 3
Recruiting NCT05228574 - Treatment of Vascular Stiffness in ADPKD Phase 4
Completed NCT04908462 - To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers Phase 1
Completed NCT03858439 - Dietary Intervention in ADPKD on Tolvaptan N/A
Recruiting NCT06391450 - Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD) Phase 4
Completed NCT03102632 - A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease N/A
Recruiting NCT05996731 - Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases N/A
Recruiting NCT06193616 - Outcome of ADPKD With Octreotide LAR
Completed NCT05646420 - Thyroid Hormones in ADPKD N/A
Completed NCT03366337 - A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX Phase 2
Active, not recruiting NCT03273413 - Statin Therapy in Patients With Early Stage ADPKD Phase 4